Let's collaborate Boehringer Ingelheim

ASCO Virtual Meeting, 29 May–2 June 2020

Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody:  initial results in patients with advanced non-small cell lung cancer

Nicolas Girard, Martin Wermke, Fabrice Barlesi, Harald Timotheus Landsteiner, Girish Jayadeva, Jürgen Alt, Björn Hackanson

Girard_VEGF_1336.11

Audio Recording

Prof Nicolas Girard's audio recording for ASCO 2020 Virtual Meeting eposter presentation at ASCO 2020 Virtual Meeting

Introduction

Introduction

Methods

Methods

Methods (cont'd)

Methods (cont'd)

References

References

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Click for Additional Content

VEGF/ANG2 INHIBITOR (BI 836880)

BI 836880: A dual inhibitor of two key pathways mediating tumour angiogenesis

PD-1 INHIBITOR (BI 754091)

BI 754091: A programmed cell death protein-1 inhibitor

RELATED INFORMATION

VEGF/Ang2 inhibitor (BI 836880) + ezabenlimab (BI 754091)

VEGF/Ang2 inhibitor (BI 836880) + Ezabenlimab

ASCO 2020

Visit our website for information on Boehringer Ingelheim's clinical data & activities at the ASCO 2020 virtual meeting
Back to top

FOR HEALTHCARE PROFESSIONAL ONLY

links_to_3rd_party.jpg